已收盤 10-03 16:00:00 美东时间
+0.090
+1.75%
Atai Life Sciences (NASDAQ:ATAI) filed to sell 45.32 million common stock. The company will not receive any proceeds from the sale of common stocks by the selling shareholder. Filing More on ATAI Life...
09-30 05:40
The latest update is out from ATAI Life Sciences ( ($ATAI) ). ATAI Life Science...
09-30 05:28
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
09-24 18:34
今日重点评级关注:Guggenheim:维持MBX Biosciences"买入"评级,目标价从44美元升至84美元;Oppenheimer:维持MBX Biosciences"跑赢大市"评级,目标价从38美元升至80美元
09-24 10:23
In the latest quarter, 5 analysts provided ratings for ATAI Life Sciences (NASD...
09-24 06:00
ATAI Life Sciences ( ($ATAI) ) has issued an announcement. On September 23, 202...
09-23 19:28
atai Life Sciences has received a $11.4 million, five-year grant from the National Institute on Drug Abuse (NIDA) to develop non-hallucinogenic 5-HT2A/2C receptor agonists for opioid use disorder (OUD). The funding will support lead optimization, preclinical studies, and IND application preparation. These compounds aim to reduce opioid addiction without hallucinogenic effects, offering a potential breakthrough in OUD treatment.
09-18 12:00
https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/
09-13 00:30
https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/
08-22 02:35